GCKR and metabolic dysfunction-associated steatotic liver disease: Two common GCKR variants (rs1260326 and rs780094) have opposing effects in T2D and NAFLD: while they are associated with decreased levels of insulin resistance and a reduced risk of T2D, they increase the level of plasma triglycerides and the risk of NAFLD.